Blueprint Medicines (BPMC) Competitors $110.05 +6.10 (+5.87%) Closing price 04:00 PM EasternExtended Trading$112.25 +2.20 (+2.00%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BPMC vs. TEVA, BGNE, GMAB, VTRS, ITCI, SMMT, MRNA, RDY, CTLT, and SRPTShould you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. Blueprint Medicines vs. Teva Pharmaceutical Industries BeiGene Genmab A/S Viatris Intra-Cellular Therapies Summit Therapeutics Moderna Dr. Reddy's Laboratories Catalent Sarepta Therapeutics Teva Pharmaceutical Industries (NYSE:TEVA) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, community ranking, earnings, risk, institutional ownership, dividends and valuation. Which has more volatility & risk, TEVA or BPMC? Teva Pharmaceutical Industries has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Is TEVA or BPMC more profitable? Teva Pharmaceutical Industries has a net margin of -5.73% compared to Blueprint Medicines' net margin of -29.48%. Teva Pharmaceutical Industries' return on equity of 42.92% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-5.73% 42.92% 7.25% Blueprint Medicines -29.48%-112.30%-26.87% Do institutionals & insiders have more ownership in TEVA or BPMC? 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in TEVA or BPMC? Teva Pharmaceutical Industries received 788 more outperform votes than Blueprint Medicines when rated by MarketBeat users. However, 68.27% of users gave Blueprint Medicines an outperform vote while only 67.82% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes132867.82% Underperform Votes63032.18% Blueprint MedicinesOutperform Votes54068.27% Underperform Votes25131.73% Which has higher valuation and earnings, TEVA or BPMC? Blueprint Medicines has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Blueprint Medicines is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$15.85B1.57-$559M-$0.85-25.84Blueprint Medicines$249.38M28.04-$506.98M-$2.11-52.16 Does the media favor TEVA or BPMC? In the previous week, Blueprint Medicines had 12 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 26 mentions for Blueprint Medicines and 14 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.64 beat Blueprint Medicines' score of 0.59 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 7 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Blueprint Medicines 10 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer TEVA or BPMC? Teva Pharmaceutical Industries currently has a consensus price target of $22.13, indicating a potential upside of 0.72%. Blueprint Medicines has a consensus price target of $122.72, indicating a potential upside of 11.51%. Given Blueprint Medicines' higher possible upside, analysts clearly believe Blueprint Medicines is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Blueprint Medicines 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65 SummaryTeva Pharmaceutical Industries beats Blueprint Medicines on 11 of the 19 factors compared between the two stocks. Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPMC vs. The Competition Export to ExcelMetricBlueprint MedicinesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.99B$6.19B$5.20B$9.14BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-52.169.7689.3117.33Price / Sales28.04306.691,265.82136.54Price / CashN/A61.4443.7535.97Price / Book51.196.055.324.80Net Income-$506.98M$154.62M$122.60M$224.91M7 Day Performance25.87%-1.67%0.61%1.77%1 Month Performance14.07%-2.34%1.50%2.22%1 Year Performance38.64%0.93%27.22%20.66% Blueprint Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPMCBlueprint Medicines1.6497 of 5 stars$110.05+5.9%$122.72+11.5%+29.1%$6.99B$249.38M-52.16640Analyst ForecastInsider TradeShort Interest ↑Analyst RevisionGap UpTEVATeva Pharmaceutical Industries1.2152 of 5 stars$20.22-3.4%$20.88+3.2%+97.0%$22.91B$16.77B-23.7937,851Analyst ForecastBGNEBeiGene2.3904 of 5 starsN/A$253.69+∞N/A$18.03B$3.32B-22.4210,600Positive NewsGMABGenmab A/S4.4691 of 5 stars$21.72-1.9%$45.20+108.1%-29.2%$14.37B$19.84B21.092,204Short Interest ↓News CoverageVTRSViatris2.3449 of 5 stars$11.75+0.7%$13.67+16.3%-3.5%$14.02B$15.05B-15.8837,000Short Interest ↑ITCIIntra-Cellular Therapies3.7933 of 5 stars$127.26+34.1%$97.23-23.6%+87.1%$13.49B$612.78M-146.27560Analyst ForecastHigh Trading VolumeSMMTSummit Therapeutics2.8045 of 5 stars$18.09+1.3%$33.57+85.6%+425.7%$13.34B$700,000.00-64.60105MRNAModerna4.7326 of 5 stars$34.09-19.3%$78.83+131.3%-67.0%$13.12B$5.06B-5.865,600Analyst ForecastOptions VolumeAnalyst RevisionNews CoverageGap DownHigh Trading VolumeRDYDr. Reddy's Laboratories2.0099 of 5 stars$15.29-0.8%$17.00+11.2%+7.4%$12.76B$3.35B24.4327,048News CoverageCTLTCatalent1.2495 of 5 stars$63.48flat$63.40-0.1%N/A$11.52B$4.42B-28.0916,900News CoverageSRPTSarepta Therapeutics4.9263 of 5 stars$117.01-6.2%$178.71+52.7%+1.4%$11.18B$1.64B93.611,314Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies TEVA Competitors BGNE Competitors GMAB Competitors VTRS Competitors ITCI Competitors SMMT Competitors MRNA Competitors RDY Competitors CTLT Competitors SRPT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BPMC) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.